Resource Directory
Connecting the right capital with the right projects
Addressing AMR requires sustained investment across the comprehensive research and development continuum, from early discovery through clinical development, commercialization, and global access. This directory maps venture capital, private equity, public agencies, philanthropic organizations, and public-private partnerships that direct capital toward the AMR response, making it easier to identify funding sources and build partnerships.
Seeking funding for your AMR project or program? Complete our Seeking Resources form, tell us about your project, and we will see if we can help.
Tell Us About Your AMR ProjectHorizon Europe–backed partnership launched in 2025 to coordinate and co-fund AMR research and innovation across human, animal, plant, and environmental health. Horizon Europe–backed partnership launched in 2025 to coordinate and co-fund AMR research and innovation across human, animal, plant, and environmental health.
Large life sciences VC that invests broadly in therapeutics and medtech, with documented anti-infective exposure. Large life sciences VC that invests broadly in therapeutics and medtech, with documented anti-infective exposure.
Platform-focused venture creation firm that builds companies around novel biology, computation, and enabling technologies. Platform-focused venture creation firm that builds companies around novel biology, computation, and enabling technologies.
UK-supported AMR fund focused on surveillance systems, laboratories, data use, and One Health capacity in low- and middle-income countries. UK-supported AMR fund focused on surveillance systems, laboratories, data use, and One Health capacity in low- and middle-income countries.
European life sciences investor with recurring exposure to anti-infectives and severe fungal or bacterial infection companies. European life sciences investor with recurring exposure to anti-infectives and severe fungal or bacterial infection companies.
Longstanding biotech investor with venture and public-market strategies across innovative therapeutics. Longstanding biotech investor with venture and public-market strategies across innovative therapeutics.
UK government AMR fund supporting research and product innovation, especially solutions relevant to low- and middle-income countries. UK government AMR fund supporting research and product innovation, especially solutions relevant to low- and middle-income countries.
WHO-linked nonprofit product development partnership focused on building and delivering new treatments for drug-resistant infections and improving access. WHO-linked nonprofit product development partnership focused on building and delivering new treatments for drug-resistant infections and improving access.
Large venture platform with a meaningful healthcare practice and documented participation in infectious-disease diagnostics financing. Large venture platform with a meaningful healthcare practice and documented participation in infectious-disease diagnostics financing.
Healthcare investor active in growth and later-stage company building across therapeutics, medtech, and diagnostics. Healthcare investor active in growth and later-stage company building across therapeutics, medtech, and diagnostics.
Japan-based global health R&D partnership that funds drugs, vaccines, and diagnostics with public-health relevance and can support AMR-relevant infectious disease innovation. Japan-based global health R&D partnership that funds drugs, vaccines, and diagnostics with public-health relevance and can support AMR-relevant infectious disease innovation.
Healthcare-focused venture firm investing across biotech, medtech, and healthtech. Healthcare-focused venture firm investing across biotech, medtech, and healthtech.
Swiss healthcare investor with a diversified private and public portfolio and documented exposure to infectious-disease diagnostics. Swiss healthcare investor with a diversified private and public portfolio and documented exposure to infectious-disease diagnostics.
Genomics and precision-health venture firm especially relevant to infectious-disease diagnostics, sequencing, and enabling tools. Genomics and precision-health venture firm especially relevant to infectious-disease diagnostics, sequencing, and enabling tools.
Biotech accelerator that can be relevant to AMR founders at the company-formation stage, especially for platform, synthetic biology, or diagnostic concepts. Biotech accelerator that can be relevant to AMR founders at the company-formation stage, especially for platform, synthetic biology, or diagnostic concepts.
UK innovation agency that funds commercial R&D across sectors and can be a practical non-dilutive source for AMR diagnostics, therapeutics, and enabling platforms. UK innovation agency that funds commercial R&D across sectors and can be a practical non-dilutive source for AMR diagnostics, therapeutics, and enabling platforms.
European public-private AMR infrastructure spanning the IMI ND4BB legacy and IHI-era AMR Accelerator efforts to move new antibacterial approaches forward. European public-private AMR infrastructure spanning the IMI ND4BB legacy and IHI-era AMR Accelerator efforts to move new antibacterial approaches forward.
Mission-driven AMR organization that co-develops and funds evidence-based interventions with low- and middle-income countries. Mission-driven AMR organization that co-develops and funds evidence-based interventions with low- and middle-income countries.
Strategic venture arm of Johnson & Johnson investing from company creation through later venture rounds across healthcare. Strategic venture arm of Johnson & Johnson investing from company creation through later venture rounds across healthcare.
Venture firm known for backing technically ambitious companies, including healthcare and diagnostics platforms. Venture firm known for backing technically ambitious companies, including healthcare and diagnostics platforms.
Stay connected so that you don't miss the latest AMR insights and updates.
